Cargando…
Fingolimod Real World Experience: Efficacy and Safety in Clinical Practice
Fingolimod is a multiple sclerosis treatment licensed in Europe since 2011. Its efficacy has been demonstrated in three large phase III trials, used in the regulatory submissions throughout the world. As usual, in these trials the inclusion and exclusion criteria were designed to obtain a homogeneou...
Autor principal: | Fonseca, Joaquim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674597/ https://www.ncbi.nlm.nih.gov/pubmed/26693475 http://dx.doi.org/10.1155/2015/389360 |
Ejemplares similares
-
Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis
por: Druart, Charlotte, et al.
Publicado: (2017) -
Efficacy and Safety of Fingolimod in Daily Practice: Experience of an Academic MS French Center
por: Roux, Thomas, et al.
Publicado: (2017) -
The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
por: Wicks, Paul, et al.
Publicado: (2016) -
Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
por: Gajofatto, Alberto, et al.
Publicado: (2015) -
Patient experience and practice trends in multiple sclerosis – clinical utility of fingolimod
por: Lee, Jong-Mi, et al.
Publicado: (2015)